{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:20:25Z","timestamp":1793974825531,"version":"4.8.0"},"reference-count":267,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","award":["PI15\/01229"],"award-info":[{"award-number":["PI15\/01229"]}],"id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","award":["PI18\/00542"],"award-info":[{"award-number":["PI18\/00542"]}],"id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","award":["EHD25PI02"],"award-info":[{"award-number":["EHD25PI02"]}],"id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006301","name":"Center for International Business Education and Research, University of Illinois at Urbana-Champaign","doi-asserted-by":"publisher","award":["S2300092_3"],"award-info":[{"award-number":["S2300092_3"]}],"id":[{"id":"10.13039\/100006301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00145"],"award-info":[{"award-number":["PI15\/00145"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/0358"],"award-info":[{"award-number":["PI18\/0358"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01427"],"award-info":[{"award-number":["PI22\/01427"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016391","name":"Societat Catalana de Digestologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000969","name":"American Institute for Cancer Research","doi-asserted-by":"publisher","award":["16-0026"],"award-info":[{"award-number":["16-0026"]}],"id":[{"id":"10.13039\/100000969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["FI19\/00222"],"award-info":[{"award-number":["FI19\/00222"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PRYCO234831"],"award-info":[{"award-number":["PRYCO234831"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019444","name":"Compass Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019444","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jhep.2025.10.020","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:24:01Z","timestamp":1761524641000},"page":"631-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":268,"title":["BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-9534","authenticated-orcid":false,"given":"Maria","family":"Reig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sanduzzi-Zamparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-4950","authenticated-orcid":false,"given":"Alejandro","family":"Forner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1814-4198","authenticated-orcid":false,"given":"Jordi","family":"Rimola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-4209","authenticated-orcid":false,"given":"Joana","family":"Ferrer-F\u00e0brega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Burrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Garcia-Criado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-7085","authenticated-orcid":false,"given":"Alba","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3209-0453","authenticated-orcid":false,"given":"Neus","family":"Llarch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Iserte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6215-2251","authenticated-orcid":false,"given":"Meritxell","family":"Moll\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2430","authenticated-orcid":false,"given":"Robin K.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8294-0992","authenticated-orcid":false,"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6417","authenticated-orcid":false,"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7123-0637","authenticated-orcid":false,"given":"Ted K.","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9606-6957","authenticated-orcid":false,"given":"Carmen","family":"Ayuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7355-7913","authenticated-orcid":false,"given":"Ferran","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-0753","authenticated-orcid":false,"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.10.020_bib1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.10.020_bib2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current strategy for staging and treatment: the BCLC update and future prospects","volume":"30","author":"Forner","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.10.020_bib4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1394143","article-title":"Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST","volume":"34","author":"Reig","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.10.020_bib7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0168-8278(99)80023-3","article-title":"A consensus conference on prognostic studies in hepatology","volume":"30","author":"Orlandi","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib11","series-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","author":"Singal","year":"2023"},{"key":"10.1016\/j.jhep.2025.10.020_bib12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2468-1253(25)00011-1","article-title":"[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study","volume":"10","author":"Nault","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end\u2013stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa0801209","article-title":"Hyponatremia and mortality among patients on the liver-transplant waiting list","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.10.020_bib17","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2021.08.050","article-title":"MELD 3.0: the model for end-stage liver disease updated for the modern era","volume":"161","author":"Kim","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib18","article-title":"Prognostic significance of mild ascites in patients with cirrhosis","author":"Chong","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2025.04.018","article-title":"Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease","volume":"83","author":"Tonon","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bjc.1993.140","article-title":"Performance status assessment in cancer patients. An inter-observer variability study","volume":"67","author":"S\u00f8rensen","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib21","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib23","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1053\/j.gastro.2021.01.233","article-title":"International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma","volume":"160","author":"Singal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib24","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/hep.26057","article-title":"Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma","volume":"57","author":"Sieghart","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib25","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.3390\/cancers12113446","article-title":"Multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors","volume":"12","author":"Londo\u00f1o","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.10.020_bib26","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/hep.24670","article-title":"Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques","volume":"54","author":"Bruix","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib27","doi-asserted-by":"crossref","unstructured":"Matute-Gonz\u00e1lez, Mario; Ronot, Maxime; Chernyak, Victoria; Sangro, Bruno; Rimola, Jordi. Response evaluation to systemic therapy in HCC: Current challenges and future perspectives. Information Hepatol. https:\/\/doi.org\/10.1097\/HEP.0000000000001621. November 19, 2025.","DOI":"10.1097\/HEP.0000000000001621"},{"key":"10.1016\/j.jhep.2025.10.020_bib28","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0037-1606213","article-title":"Is propensity score analysis a valid surrogate of randomization for the avoidance of allocation bias?","volume":"37","author":"Torres","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.10.020_bib30","article-title":"Statistical methods for baseline adjustment and cohort analysis in Korean national health insurance claims data: a review of PSM, IPTW, and survival analysis with future directions","volume":"40","author":"Kim","year":"2025","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jhep.2025.10.020_bib31","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1002\/sim.8659","article-title":"Balancing vs modeling approaches to weighting in practice","volume":"39","author":"Chattopadhyay","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2025.10.020_bib32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1547-5069.1990.tb00225.x","article-title":"Reconceptualization of the uncertainty in illness theory","volume":"22","author":"Mishel","year":"1990","journal-title":"Image J Nurs Scholarsh"},{"key":"10.1016\/j.jhep.2025.10.020_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1547-5069.2002.00127.x","article-title":"A concept analysis of uncertainty in illness","volume":"34","author":"McCormick","year":"2002","journal-title":"J Nurs Scholarsh"},{"key":"10.1016\/j.jhep.2025.10.020_bib34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/bmj.38336.482720.8F","article-title":"The nature of medical evidence and its inherent uncertainty for the clinical consultation: qualitative study","volume":"330","author":"Griffiths","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2025.10.020_bib35","article-title":"Impact of waiting time on post-transplant survival for recipients with hepatocellular carcinoma: a natural experiment randomized by blood group","volume":"5","author":"Beumer","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.10.020_bib36","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.21037\/qims-20-1411","article-title":"Impact of waiting time on hepatocellular carcinoma progression in patients undergoing curative tumour ablation","volume":"12","author":"Ong","year":"2022","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib37","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.29907","article-title":"Reframing the approach to patients with hepatocellular carcinoma: longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy","volume":"68","author":"Firl","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/lt.24360","article-title":"Intention to treat outcome of T1 hepatocellular carcinoma with the \u201cwait and not ablate\u201d approach until meeting T2 criteria for liver transplant listing","volume":"22","author":"Mehta","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib39","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s10620-024-08441-6","article-title":"Effects of exercise training on muscle mass and physical function in patients with hepatocellular carcinoma after diagnosis: a systematic review","volume":"69","author":"Marcantei","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2025.10.020_bib40","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.dld.2016.11.013","article-title":"Portal vein thrombosis: the role of imaging in the clinical setting","volume":"49","author":"Margini","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.10.020_bib43","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2214\/ajr.160.6.8388621","article-title":"Fine-needle aspiration biopsy of portal vein thrombus: value in detecting malignant thrombosis","volume":"160","author":"Vilana","year":"1993","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.jhep.2025.10.020_bib44","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib45","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0016-5085(95)90450-6","article-title":"Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma","volume":"108","author":"Adachi","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib47","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","article-title":"Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection","volume":"81","author":"Fuster-Anglada","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(93)90724-Q","article-title":"Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma","volume":"105","author":"Nagasue","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib49","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/01.sla.0000143808.63039.51","article-title":"Is primary resection and salvage transplantation for hepatocellular carcinoma a reasonable strategy?","volume":"240","author":"Poon","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib50","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.1840140510","article-title":"Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses","volume":"14","author":"Shirabe","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib51","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/lt.20202","article-title":"High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation","volume":"10","author":"Sala","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib52","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hep.28339","article-title":"Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection","volume":"63","author":"Ferrer-F\u00e0brega","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib53","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/liv.15900","article-title":"Upfront multi-bipolar radiofrequency ablation for <scp>HCC<\/scp> in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence","volume":"44","author":"Boros","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.10.020_bib54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/lt.22103","article-title":"Hepatocellular carcinoma: ablate and wait versus rapid transplantation","volume":"16","author":"Roberts","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000521665","article-title":"Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF trial)","volume":"11","author":"Takayama","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jhep.2014.03.037","article-title":"Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma","volume":"61","author":"Cucchetti","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib57","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"Feng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib58","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/hep.23466","article-title":"Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma","volume":"51","author":"Cho","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib59","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jhep.2018.12.027","article-title":"Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients","volume":"70","author":"Doyle","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib60","article-title":"Minimally invasive hepatectomy vs. thermoablation for single small (\u22643 cm) hepatocellular carcinoma: a weighted real-life national comparison","volume":"7","author":"Giuliante","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.10.020_bib61","article-title":"Novel benchmark for robotic liver resection \u2013 bridging tradition with innovation","author":"Li","year":"2025","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/bjs\/znab376","article-title":"Laparoscopic versus open resection of hepatocellular carcinoma in patients with cirrhosis: meta-analysis","volume":"109","author":"Kabir","year":"2021","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib63","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib64","article-title":"Microwave ablation vs. single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: a randomized-controlled trial","volume":"7","author":"Sugimoto","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.10.020_bib65","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib66","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1200\/JCO-24-01532","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: a randomized, open-label, controlled trial","volume":"43","author":"Xi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib67","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(96)70070-7","article-title":"Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure","volume":"111","author":"Bruix","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib68","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hep.27431","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis","volume":"61","author":"Berzigotti","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib69","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jamasurg.2016.1121","article-title":"Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma","volume":"151","author":"Citterio","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib70","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib71","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2020.10.003","article-title":"Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis","volume":"74","author":"Ferrusqu\u00eda-Acosta","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib72","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2021.09.029","article-title":"Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: is it real and how to measure it?","volume":"76","author":"Baffy","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib73","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib74","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/hep.27760","article-title":"A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial\u2013mesenchymal transition\u2013independent manner","volume":"62","author":"Fang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2023.11.030","article-title":"Battle of the biopsies: role of tissue and liquid biopsy in hepatocellular carcinoma","volume":"80","author":"Lehrich","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib76","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/cancers15030817","article-title":"Genetics of hepatocellular carcinoma: from tumor to circulating DNA","volume":"15","author":"Campani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.10.020_bib77","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2019.08.032","article-title":"Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis","volume":"72","author":"Berardi","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib78","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00464-017-5930-1","article-title":"Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study","volume":"32","author":"Molina","year":"2018","journal-title":"Surg Endosc"},{"key":"10.1016\/j.jhep.2025.10.020_bib79","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.10.020_bib80","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1053\/j.gastro.2008.02.091","article-title":"Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma","volume":"134","author":"Ishizawa","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib81","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ajg.2011.425","article-title":"Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors","volume":"107","author":"Shiina","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.10.020_bib82","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.gastro.2005.04.009","article-title":"A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma","volume":"129","author":"Shiina","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib83","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.12.004","article-title":"Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis","volume":"52","author":"Germani","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","article-title":"Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY trial)","volume":"117","author":"M\u00e9ndez Romero","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib85","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cncr.30008","article-title":"Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation","volume":"122","author":"Takeda","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib86","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib87","article-title":"Overall survival among patients with hepatocellular carcinoma treated with external beam radiation therapy: individual patient data outcomes from a multinational cohort","author":"Moon","year":"2025","journal-title":"ILCA"},{"key":"10.1016\/j.jhep.2025.10.020_bib88","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","article-title":"Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group","volume":"50","author":"Salem","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhep.2025.10.020_bib89","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2025.10.020_bib90","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"90 Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2025.10.020_bib91","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","article-title":"Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection","volume":"59","author":"Vouche","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib92","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2023.08.016","article-title":"Defining minimum treatment parameters of ablative radiation therapy in patients with hepatocellular carcinoma: an expert consensus","volume":"14","author":"Yanagihara","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib93","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.3390\/cancers15204914","article-title":"The current evidence of intensity-modulated radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"15","author":"Jang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.10.020_bib94","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/cncr.34965","article-title":"Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: results of a randomized clinical trial","volume":"129","author":"Bush","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib95","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.3390\/curroncol29110692","article-title":"Stereotactic radiotherapy after incomplete transarterial (Chemo-) embolization (TAE\\TACE) versus exclusive TAE or TACE for treatment of inoperable HCC: a phase III trial (NCT02323360)","volume":"29","author":"Comito","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib96","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/lt.21109","article-title":"Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study","volume":"13","author":"Dharancy","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib97","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/SLA.0000000000001384","article-title":"Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation","volume":"262","author":"Agopian","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib98","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhep.2015.01.023","article-title":"Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?","volume":"63","author":"Allard","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib99","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/lt.500050307","article-title":"Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma","volume":"5","author":"Harnois","year":"1999","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib100","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/hep.24246","article-title":"Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas","volume":"53","author":"Golfieri","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib101","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jvir.2025.02.016","article-title":"Comparative radiologic response assessment after transarterial chemoembolization, percutaneous ablation, and multimodal treatment: radiologic-pathologic correlation in 81 tumors","volume":"36","author":"Badar","year":"2025","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.01.008","article-title":"Yttrium-90 radioembolization for hepatocellular carcinoma is associated with a lower risk of liver transplant waitlist dropout compared to chemoembolization","author":"Kim","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib103","article-title":"SBRT for bridging and downstaging HCC before transplant","volume":"7","author":"Li","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.10.020_bib104","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.21037\/jgo-23-261","article-title":"Comparison of transarterial bland embolization and drug-eluting beads transarterial chemoembolization for very early and early hepatocellular carcinoma not amenable for surgery or ablation: a single center retrospective data analysis","volume":"14","author":"Cathomas","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib105","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.crad.2022.09.120","article-title":"Transarterial chemoembolisation for very early and early stage hepatocellular carcinoma: single-centre experience","volume":"78","author":"Hashem","year":"2023","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib106","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jvir.2025.05.009","article-title":"Histopathologic response and oncologic outcomes after segmental and subsegmental transarterial chemoembolization and radioembolization for hepatocellular carcinoma","volume":"36","author":"Sher","year":"2025","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib107","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jhep.2025.01.005","article-title":"Radiation segmentectomy for early hepatocellular carcinoma is curative","volume":"82","author":"Salem","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib108","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib109","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamasurg.2024.1184","article-title":"Liver resection vs nonsurgical treatments for patients with early multinodular hepatocellular carcinoma","volume":"159","author":"Vitale","year":"2024","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.17998\/jlc.2023.08.24","article-title":"Clinical outcome of surgical resection for multifocal T2-T3 hepatocellular carcinoma up to 3 nodules: a comparative analysis with a single nodule","volume":"23","author":"Yu","year":"2023","journal-title":"J Liver Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib111","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.241096","article-title":"Transarterial chemoembolization with radiofrequency ablation versus surgical resection for small late-recurrence hepatocellular carcinoma","volume":"314","author":"Zhang","year":"2025","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2025.10.020_bib112","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cac2.12614","article-title":"Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial","volume":"44","author":"Yuan","year":"2024","journal-title":"Cancer Commun"},{"key":"10.1016\/j.jhep.2025.10.020_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1101162","article-title":"Hepatectomy versus transcatheter arterial chemoembolization for resectable BCLC stage A\/B hepatocellular carcinoma beyond Milan criteria: a randomized clinical trial","volume":"13","author":"Fang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib114","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/JS9.0000000000000839","article-title":"A multicenter case\u2013controlled study on laparoscopic hepatectomy versus microwave ablation as first-line therapy for 3\u20135 cm hepatocellular carcinoma in patients aged 60 and older","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib115","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO-24-02030","article-title":"Surgery versus ablation for hepatocellular carcinoma: a randomized controlled trial (SURF-RCT trial) and a nonrandomized prospective observational trial (SURF-Cohort trial)","volume":"43","author":"Kawaguchi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib116","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib117","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ejso.2016.12.004","article-title":"Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: short to mid-term results","volume":"43","author":"Fr\u00fchling","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib118","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamasurg.2024.2339","article-title":"Histotripsy\u2014a novel and intriguing technique of liver ablation","volume":"160","author":"Rog","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.gassur.2025.102000","article-title":"The first international experience with histotripsy: a safety analysis of 230 cases","volume":"29","author":"Wehrle","year":"2025","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib120","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233051","article-title":"The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors","volume":"312","author":"Mendiratta-Lala","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2025.10.020_bib121","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00464-025-11566-y","article-title":"Treatment strategies for solitary hepatocellular carcinoma: comparative outcomes of radiofrequency ablation vs. laparoscopic liver resection based on tumor location","volume":"39","author":"Lee","year":"2025","journal-title":"Surg Endosc"},{"key":"10.1016\/j.jhep.2025.10.020_bib122","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12893-024-02432-0","article-title":"Laparoscopic-assisted microwave ablation in treatment of small hepatocellular carcinoma: safety and efficacy in comparison with laparoscopic hepatectomy","volume":"24","author":"Wei","year":"2024","journal-title":"BMC Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib123","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1007\/s00330-023-10268-0","article-title":"Microwave ablation versus laparoscopic resection for hepatocellular carcinoma in patients with clinically significant portal hypertension: a propensity score\u2013matched study of postoperative liver decompensation","volume":"34","author":"Yu","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib124","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.3390\/cancers15133269","article-title":"Risk of treatment failure and death after ablation in hepatocellular carcinoma patients\u2014a multiparametric prediction","volume":"15","author":"Mu\u00f1oz-Mart\u00ednez","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.10.020_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109623","article-title":"Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: a multicenter retrospective study","volume":"138","author":"Yang","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib126","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00535-003-1181-0","article-title":"Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation","volume":"38","author":"Hori","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.10.020_bib127","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejrad.2010.02.010","article-title":"Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation","volume":"79","author":"Yang","year":"2011","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib128","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/cncr.11168","article-title":"Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation","volume":"97","author":"Komorizono","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jjco\/hym086","article-title":"Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome","volume":"37","author":"Zytoon","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3350\/cmh.2016.0048","article-title":"Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma","volume":"22","author":"Cho","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2024.05.002","article-title":"The Barthel Index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: a multicenter cohort study","volume":"237","author":"Yang","year":"2024","journal-title":"Am J Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib132","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","article-title":"Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference","volume":"104","author":"Mehta","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2025.10.020_bib133","doi-asserted-by":"crossref","DOI":"10.1097\/LVT.0000000000000589","article-title":"The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma","author":"Kodali","year":"2025","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib134","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1053\/j.gastro.2004.09.032","article-title":"Chemoembolization for hepatocellular carcinoma","volume":"127","author":"Bruix","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"Golfieri","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib136","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib137","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","article-title":"Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads","volume":"56","author":"Guiu","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib138","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00330-016-4488-y","article-title":"Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion","volume":"27","author":"Monier","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib139","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","article-title":"Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma","volume":"33","author":"Malagari","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib140","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone","volume":"34","author":"Brown","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib141","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jvir.2024.09.005","article-title":"Comparison of the effectiveness of transarterial bland embolization and transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a propensity score\u2013matched study of 1,008 patients","volume":"36","author":"Zhang","year":"2025","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib142","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/cancers13040812","article-title":"Comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: a propensity score analysis","volume":"13","author":"Roth","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.10.020_bib143","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00270-024-03666-4","article-title":"Transarterial chemoembolization with epirubicin-loaded microspheres for hepatocellular carcinoma: a prospective, single-arm, multicenter, phase 2 study (STOPPER trial)","volume":"47","author":"Zhu","year":"2024","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib144","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study","volume":"70","author":"Wang","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib145","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.23904","article-title":"Alpha-fetoprotein level > 1000 ng\/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria","volume":"20","author":"Hameed","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib146","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib147","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib148","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrgastro.2016.193","article-title":"Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches","volume":"14","author":"Sapisochin","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib149","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.23332","article-title":"Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models","volume":"51","author":"Navasa","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib151","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design","volume":"56","author":"Burrel","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib152","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2011.10.021","article-title":"Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines","volume":"56","author":"Takayasu","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib153","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00270-023-03362-9","article-title":"Transarterial chemoembolization with anthracyclines-loaded polyethylene glycol drug eluting microspheres for the treatment of hepatocellular carcinoma: a pooled multicentric analysis of survival in 580 patients","volume":"46","author":"Veloso Gomes","year":"2023","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib154","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000522547","article-title":"Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","article-title":"Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma","volume":"140","author":"Salem","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib156","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.020_bib157","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/cncr.24884","article-title":"Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma","volume":"116","author":"Carr","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib158","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hep.23485","article-title":"A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma","volume":"51","author":"Cabibbo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib159","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3390\/cancers11060879","article-title":"Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization","volume":"11","author":"Antkowiak","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.10.020_bib160","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jvir.2022.11.036","article-title":"Radioembolization for intermediate-stage hepatocellular carcinoma maintains liver function and permits systemic therapy at progression","volume":"34","author":"Ranganathan","year":"2023","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib161","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35720","article-title":"Meta-analysis of randomized controlled trials of external-beam radiation versus transarterial chemoembolization for hepatocellular carcinoma","volume":"131","author":"Kuehnle","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib162","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000487311","article-title":"Effectiveness of particle radiotherapy in various stages of hepatocellular carcinoma: a pilot study","volume":"7","author":"Sorin","year":"2018","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib163","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib164","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib166","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.542","article-title":"LBA2 TALENTACE: a phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib167","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib168","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12916-025-04159-y","article-title":"Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial","volume":"23","author":"Kan","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.jhep.2025.10.020_bib169","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41392-024-02012-x","article-title":"Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III tr","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jhep.2025.10.020_bib170","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.10.020_bib171","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2025.10.020_bib172","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib174","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib175","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib176","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.10.020_bib177","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib178","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","article-title":"Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib179","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib180","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib181","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib182","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib183","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S2468-1253(25)00059-7","article-title":"Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial","volume":"10","author":"Shi","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib184","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib185","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jhep.2025.10.020_bib186","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib187","article-title":"Hepatocellular carcinoma with macrovascular invasion: review and survival meta-analysis with minimal prognostic criteria","author":"Fortuny","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib188","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib189","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.10.020_bib191","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib192","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib193","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.22.00620","article-title":"Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib194","article-title":"Second-line pembrolizumab for advanced HCC: meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies","volume":"7","author":"Finn","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.10.020_bib195","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2024.03.033","article-title":"Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment","volume":"81","author":"Chan","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib196","doi-asserted-by":"crossref","first-page":"S579","DOI":"10.1016\/S0168-8278(23)01381-8","article-title":"Interim analysis of the ACTION trial: cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance","volume":"78","author":"Sanduzzi-Zamparelli","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib197","first-page":"1","article-title":"Multicenter phase 2 trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on atezolizumab plus bevacizumab (REGONEXT)","author":"Cheon","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib198","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1200\/JCO.2022.40.4_suppl.428","article-title":"Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile","volume":"40","author":"Sanduzzi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib199","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2024.42.16_suppl.4007","article-title":"International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI)","volume":"42","author":"El-Khoueiry","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib200","article-title":"Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab","author":"Kim","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib201","article-title":"Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association","volume":"57","author":"Allaire","year":"2025","journal-title":"Lancet Reg Heal - Eur"},{"key":"10.1016\/j.jhep.2025.10.020_bib202","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/hep.27729","article-title":"Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib","volume":"62","author":"Iavarone","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10637-016-0323-1","article-title":"Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib","volume":"34","author":"Ogasawara","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jhep.2025.10.020_bib204","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/liv.14731","article-title":"Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab","volume":"41","author":"Reig","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.10.020_bib205","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib206","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00270-020-02444-2","article-title":"The pattern of progression defines post-progression survival in patients with hepatocellular carcinoma treated with SIRT","volume":"43","author":"de la Torre-Al\u00e1ez","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jhep.2025.10.020_bib207","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/HEP.0000000000000636","article-title":"Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab","volume":"79","author":"Campani","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib208","first-page":"275","article-title":"Reporting time toxicity in prospective cancer clinical trials: a scoping review","volume":"32","author":"Quinn","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib209","first-page":"572","article-title":"Productivity loss by cancer stage in patients newly diagnosed with hepatocellular carcinoma: a claims database analysis","volume":"30","author":"Cheng","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jhep.2025.10.020_bib210","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1007\/s12325-024-02939-1","article-title":"Patient experience of hepatocellular carcinoma and their treatment goals: an international qualitative study and patient journey map","volume":"41","author":"W\u00f6rns","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jhep.2025.10.020_bib211","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.2217\/fon-2021-0697","article-title":"Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study","volume":"17","author":"Lo","year":"2021","journal-title":"Futur Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib212","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/SLA.0000000000005373","article-title":"Hepatectomy versus sorafenib in advanced nonmetastatic hepatocellular carcinoma","volume":"275","author":"Famularo","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2025.10.020_bib213","first-page":"1","article-title":"Prognosis of hepatectomy versus systemic chemotherapy based on oncological resectability criteria for borderline resectable hepatocellular carcinoma","author":"Komatsu","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000539897","article-title":"Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib215","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70217","article-title":"Vascular invasion within the resectability criteria is a prognostic factor in patients treated with atezolizumab and bevacizumab","volume":"45","author":"Matono","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.10.020_bib216","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2967\/jnumed.123.266211","article-title":"Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial","volume":"65","author":"Garin","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jhep.2025.10.020_bib217","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib218","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib219","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/gutjnl-2024-332125","article-title":"Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events","volume":"74","author":"De Martin","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.10.020_bib220","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70264","article-title":"Breaking barriers for intensive care admission in patients with advanced HCC on immunotherapy","volume":"45","author":"Fortuny","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.10.020_bib221","doi-asserted-by":"crossref","first-page":"348","DOI":"10.18632\/oncotarget.28721","article-title":"Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma","volume":"16","author":"da Fonseca","year":"2025","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2025.10.020_bib222","article-title":"Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies","volume":"6","author":"Campani","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.10.020_bib223","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.04.028","article-title":"Hepatocellular carcinoma in people living with HIV","author":"Fulgenzi","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib224","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1200\/JCO.22.02459","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: a real-world report from the cancer therapy using checkpoint inhibitors in people living with HIV-international (CATCH-IT) consortium","volume":"41","author":"El","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101153","article-title":"Hepatocellular cancer therapy in patients with HIV infection: disparities in cancer care, trials enrolment, and cancer-related research","volume":"14","author":"Negri","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib226","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.18.00885","article-title":"Influence of HIV infection on the natural history of hepatocellular carcinoma: results from a global multicohort study","volume":"37","author":"Pinato","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib227","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.24.00857","article-title":"Liver transplantation for hepatocellular carcinoma: an expanding cornerstone of care in the era of immunotherapy","volume":"43","author":"Magyar","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib228","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MOT.0000000000001228","article-title":"Liver transplantation for hepatocellular carcinoma following immunotherapy","volume":"30","author":"Marino","year":"2025","journal-title":"Curr Opin Organ Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib229","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12885-025-14446-9","article-title":"Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study","volume":"25","author":"Ye","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib230","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/lt.26264","article-title":"Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation: a retrospective study","volume":"27","author":"Iavarone","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib231","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/ajt.15551","article-title":"Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation","volume":"19","author":"Iavarone","year":"2019","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib232","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12328-024-01946-7","article-title":"Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series","volume":"17","author":"Sakaguchi","year":"2024","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.10.020_bib233","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/liv.14436","article-title":"International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis","volume":"40","author":"D\u00edaz-Gonz\u00e1lez","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.10.020_bib234","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ueg2.12510","article-title":"Systemic therapies in hepatocellular carcinoma: a revolution?","volume":"12","author":"Fortuny","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2025.10.020_bib235","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib236","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib237","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hepr.12542","article-title":"Response evaluation criteria in cancer of the liver (RECICL) (2015 revised version)","volume":"46","author":"Kudo","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2025.10.020_bib238","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.10.020_bib239","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib240","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib241","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib242","unstructured":"https:\/\/www.acr.org\/Clinical-Resources\/Clinical-Tools-and-Reference\/Reporting-and-Data-Systems\/LI-RADS n.d."},{"key":"10.1016\/j.jhep.2025.10.020_bib243","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2025.10.020_bib244","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/HEP.0000000000001231","article-title":"Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study","volume":"82","author":"Xu","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib245","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hep.32613","article-title":"Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF\/TKI and immunotherapy","volume":"76","author":"Tran","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.020_bib246","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2025.10.020_bib247","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib248","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib249","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1186\/s12885-025-14250-5","article-title":"Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial","volume":"25","author":"Yalikun","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib250","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010035","article-title":"Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria","volume":"13","author":"Li","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib251","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jhep.2025.10.020_bib252","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4149\/neo_2023_230806N413","article-title":"Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial","volume":"70","author":"Liu","year":"2024","journal-title":"Neoplasma"},{"key":"10.1016\/j.jhep.2025.10.020_bib253","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2025.10.020_bib254","doi-asserted-by":"crossref","DOI":"10.2739\/kurumemedj.MS6834010","article-title":"Preoperative chemotherapy followed by hepatectomy for potentially resectable UICC7 stage IIIA, IIIB hepatocellular carcinoma; A phase II clinical trial","volume":"68","author":"Goto","year":"2021","journal-title":"Kurume Med J"},{"key":"10.1016\/j.jhep.2025.10.020_bib255","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib256","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12916-025-04110-1","article-title":"Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial","volume":"23","author":"Shen","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.jhep.2025.10.020_bib257","doi-asserted-by":"crossref","DOI":"10.17235\/reed.2025.11029\/2024","article-title":"Epidemiological characteristics of contemporary patients with untreated hepatocellular carcinoma","author":"Gonz\u00e1lez-S\u00e1nchez","year":"2025","journal-title":"Rev Espa\u00f1ola Enfermedades Dig"},{"key":"10.1016\/j.jhep.2025.10.020_bib258","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2021.06.018","article-title":"Towards a new definition of decompensated cirrhosis","volume":"76","author":"D\u2019Amico","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib259","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(25)00095-0","article-title":"Recompensation in decompensated cirrhosis","author":"Premkumar","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib260","article-title":"Mechanisms and implications of recompensation in cirrhosis","volume":"6","author":"Piano","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.10.020_bib261","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/liv.15676","article-title":"Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis","volume":"43","author":"Hofer","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.10.020_bib262","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","article-title":"Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis","volume":"21","author":"Hofer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib263","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.10.020_bib264","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.04.026","article-title":"Incidence and clinical significance of recompensation after HCV cure","author":"Semmler","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.02.041","article-title":"Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C","author":"S\u00e1nchez-Torrijos","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.020_bib266","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1200\/JCO.2013.49.9202","article-title":"Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases","volume":"31","author":"Soliman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.10.020_bib267","doi-asserted-by":"crossref","unstructured":"Iserte G, Llarch N, Moon AM, Reig M. Optimizing liver cancer care through BCLC principles. Seminar Liver Diseases. https:\/\/doi.org\/10.1055\/a-2769-7224.","DOI":"10.1055\/a-2769-7224"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2026.03.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000}},{"DOI":"10.1016\/j.jhep.2026.03.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825025711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825025711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:56:32Z","timestamp":1777528592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825025711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":267,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0168827825025711"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}